Publications

Find coverage of the latest original articles on scleroderma, focusing on those with data on therapeutic interventions and those that have clinical impact.

Publications

June 2025

View Slides

EULAR recommendations for the treatment of systemic sclerosis: 2023 update

Ann Rheum Dis 2025;84:29–40 DOI: 10.1136/ard-2024-226430

Del Galdo et al. formed a new task force to update the EULAR recommendations for the pharmacological management of systemic sclerosis (SSc). The task force agreed on 22 new recommendations covering eight clinical/organ domains: Raynaud’s phenomenon (RP), digital ulcers, pulmonary arterial hypertension (PAH), musculoskeletal, skin fibrosis, interstitial lung disease (ILD), gastrointestinal, and renal crisis.

more…

Keywords:

View Slides

Comparative efficacy of immunosuppressive therapies in the treatment of diffuse cutaneous systemic sclerosis

ACR Open Rheumatol 2025;7:e70004 DOI: 10.1002/acr2.70004.

White et al. report a post hoc analysis of the RESOLVE-1 trial comparing immunosuppressive therapies in diffuse cutaneous systemic sclerosis (dcSSc), finding numerically greater improvement in modified Rodnan skin score and stabilisation of lung function with mycophenolate mofetil (MMF), particularly in patients with early-stage disease and anti–topoisomerase 1 antibodies. These findings strongly support MMF as a preferred background therapy in this population.

more…